Market Cap : 3.87 B | Enterprise Value : 4.16 B | PE Ratio : At Loss | PB Ratio : 7.49 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil. Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-397.9 Mil. Therefore, Guardant Health's EV-to-EBIT ratio for today is -10.46.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil. Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-373.4 Mil. Therefore, Guardant Health's EV-to-EBITDA ratio for today is -11.15.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil. Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $391.1 Mil. Therefore, Guardant Health's EV-to-Revenue ratio for today is 10.64.
The historical data trend for Guardant Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Guardant Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Guardant Health's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
Enterprise Value (A: Dec. 2021 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 10178.73534 | + | 0 | + | 1360.874 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 12.856 | + | 0 | - | 932.748 |
= | 10,619.7 |
Guardant Health's Enterprise Value for the quarter that ended in Mar. 2022 is calculated as
Enterprise Value (Q: Mar. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 6751.1808 | + | 0 | + | 1360.84 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 16.556 | + | 0 | - | 962.266 |
= | 7,166.3 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Guardant Health's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 4162.851 | / | -397.899 | |
= | -10.46 |
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-397.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Guardant Health's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 4162.851 | / | -373.437 | |
= | -11.15 |
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-373.4 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Guardant Health's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 4162.851 | / | 391.087 | |
= | 10.64 |
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $391.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Guardant Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Fool 2022-03-08
By Zacks 2021-07-19
By Seekingalpha 2022-01-03
By Fool 2022-01-12
By tipranks.com 2022-03-10
By Fool 2022-03-18
By Seekingalpha 2021-11-04
By Fool 2021-10-01
By Zacks 2022-01-27
By Zacks 2022-01-28
By Zacks 2021-11-04
By Zacks 2022-01-26
By Zacks 2022-02-23
By Zacks 2021-07-30